Can analysts adopt a bullish outlook for Bristol-Myers Squibb Company (NYSE:BMY)?

March 17, 2018 - By Linda Rogers

 Can analysts adopt a bullish outlook for Bristol Myers Squibb Company (NYSE:BMY)?
Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It increased, as 62 investors sold Bristol-Myers Squibb Company shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.
Lmr Llp reported 0.05% in Bristol-Myers Squibb Company (NYSE:BMY). Hgk Asset Management Inc invested 2.4% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Moreover, First Eagle Inv Mgmt Ltd has 0.01% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 49,229 shares. Axa owns 292,142 shares. Fisher Asset Mngmt Ltd Co invested in 0.05% or 504,493 shares. Quantitative Systematic Strategies Ltd Limited Liability Company invested in 0.66% or 39,136 shares. Tirschwell And Loewy Incorporated invested in 9,900 shares. Sumitomo Life Ins reported 54,978 shares stake. Huntington Bancshares owns 588,225 shares or 0.63% of their US portfolio. The Illinois-based Chicago Equity Prns Limited Liability Com has invested 0.01% in Bristol-Myers Squibb Company (NYSE:BMY). Ledyard Natl Bank holds 30,034 shares. Johnson Fincl Grp Inc Incorporated has 0.09% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 10,927 shares. American Century Inc reported 0.15% stake. 1832 Asset Mgmt Lp has 0% invested in Bristol-Myers Squibb Company (NYSE:BMY). Davidson Garrard, Virginia-based fund reported 44,763 shares.

Since December 12, 2017, it had 1 buying transaction, and 1 insider sale for $85,985 activity. Samuels Theodore R. II bought 4,000 shares worth $249,187.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 21 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 11 Hold. Therefore 33% are positive. Bristol-Myers Squibb Company had 76 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by UBS on Friday, August 19. Barclays Capital maintained it with “Equal Weight” rating and $70 target in Tuesday, December 1 report. The stock has “Outperform” rating by Robert W. Baird on Wednesday, April 26. Atlantic Securities initiated Bristol-Myers Squibb Company (NYSE:BMY) on Friday, December 18 with “Underweight” rating. Hilliard Lyons initiated the stock with “Neutral” rating in Monday, May 23 report. The rating was maintained by BMO Capital Markets on Tuesday, February 6 with “Underperform”. SunTrust maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Monday, October 16. SunTrust has “Hold” rating and $55.0 target. The firm has “Buy” rating given on Monday, July 17 by Jefferies. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by Deutsche Bank on Friday, October 28. SunTrust upgraded the shares of BMY in report on Monday, October 30 to “Buy” rating. Below is a list of Bristol-Myers Squibb Company (NYSE:BMY) latest ratings and price target changes.

05/03/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $64 New Target: $68 Maintain
26/02/2018 Broker: Jefferies Rating: Hold New Target: $72.0 Maintain
28/02/2018 Broker: DZ Bank Old Rating: Buy New Rating: Hold Downgrade
16/02/2018 Broker: Citigroup Rating: Buy New Target: $78.0 Maintain
15/02/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
06/02/2018 Broker: BMO Capital Markets Old Rating: Underperform New Rating: Underperform Old Target: $52 New Target: $51 Maintain
06/02/2018 Broker: Leerink Swann Rating: Buy New Target: $76.0 Maintain
16/11/2017 Broker: Jefferies Rating: Hold New Target: $68.0 Maintain
13/11/2017 Broker: BMO Capital Markets Rating: Sell New Target: $49.0 Maintain
30/10/2017 Broker: SunTrust Rating: Buy Upgrade

The stock increased 0.53% or $0.35 during the last trading session, reaching $66.6. About 9.51 million shares traded or 27.31% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since March 17, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Bristol-Myers Squibb Company discovers, develops, licenses, makes, markets, and distributes biopharmaceutical products worldwide. The company has market cap of $108.73 billion. The firm offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection . It has a 109.18 P/E ratio. The Company’s products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.